Full Breakdown
Myriad Genetics' Precise MRD Test Shows Promise in Oligometastatic Clear-Cell Renal Cell Carcinoma
9/6/2025, 12:39:54 PM
Study Overview and Key Findings
On September 4, 2025, Myriad Genetics, Inc. announced the publication of a study in *The Lancet Oncology* that evaluates the effectiveness of its molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). The study aimed to assess whether ultrasensitive MRD testing could enhance patient care by identifying those who might benefit from metastasis-directed radiation therapy (MDT) without the need for systemic treatments.
The Phase 2 trial revealed that 94% of patients tested at baseline had circulating tumor DNA (ctDNA) levels below 100 parts per million (ppm), indicating the test's sensitivity in detecting low tumor burdens. Patients who tested positive for ctDNA prior to MDT progressed to systemic therapy within a median of 27 months, while those who tested negative maintained MDT for a median of 54 months without compromising overall survival rates, which were 94% at two years and 87% at three years.
Implications for Treatment
Chad Tang, MD, the principal investigator from The University of Texas MD Anderson Cancer Center, noted that the study demonstrated MDT's ability to delay systemic therapy initiation in ctDNA-negative patients, suggesting ctDNA as a promising biomarker for identifying candidates for MDT. Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics, emphasized the test's capacity to detect a wide range of ctDNA levels, which could inform treatment decisions in renal cancer and potentially other cancers, such as breast cancer.
Official Statements & Responses
Myriad Genetics expressed optimism about the findings, highlighting the potential for Precise MRD to facilitate treatment de-escalation and minimize side effects associated with systemic therapies. The company plans to further investigate the performance of Precise MRD across various cancer types, reinforcing its commitment to advancing precision medicine.
Criticism & Opposition
While the study presents promising results, some experts caution against over-reliance on ctDNA as a sole indicator for treatment decisions. Critics argue that further validation in larger, diverse populations is necessary to confirm the test's efficacy and generalizability across different clinical settings.
Conflicting Reports & Gaps
The study's findings are part of an ongoing discourse regarding the role of ctDNA in cancer management. Discrepancies exist in the literature regarding the optimal thresholds for ctDNA detection and their implications for treatment pathways. Future research is needed to address these gaps and establish standardized protocols for ctDNA utilization in clinical practice.
What's Next
The ongoing exploration of the Precise MRD test's applications in renal cancer and beyond is expected to continue, with additional studies planned to evaluate its effectiveness in various oncological contexts. As Myriad Genetics advances its research, the medical community will be closely monitoring developments that could reshape cancer treatment paradigms.
